Divi’s Labs, a leading pharmaceutical and biotechnology company, has announced its intention to enter into a long-term supply agreement with a customer, alongside plans for capacity expansion at its manufacturing facility. The company revealed this development in a press statement issued on April 25.
According to the statement, the proposed capacity addition at the manufacturing facility will require an estimated investment of Rs 650-700 crore, which will be funded through internal accruals. The new facility is projected to become operational around January 2027. However, due to the confidentiality agreement signed with the customer, Divi’s Labs refrained from disclosing further quantitative details regarding the supply agreement.
Established in October 1990, Divi’s Laboratories has emerged as a prominent player in the pharmaceutical and biotechnology sectors, specializing in generic Active Pharmaceutical Ingredients (API), custom synthesis, and nutraceuticals. The company, promoted by Dr. Murli K Divi, holds a global leadership position in Contract Research and Manufacturing Services (CRAMS) and generic APIs.
Divi’s serves therapeutic segments including cardiovascular, anti-inflammatory, anti-cancer, and central nervous system drugs.In its financial report for the December quarter, Divi’s Laboratories recorded a 17 percent year-on-year rise in consolidated profit, reaching Rs 358 crore. Revenue also witnessed an 8.6 percent increase year-on-year, reaching Rs 1,855 crore.